/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png
0
0
David Anderson
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png
David Anderson2023-09-18 15:23:232023-09-19 08:07:25Peptilogics Reports Positive 180-Day Top Line Interim Data From Phase 1b Trial of PLG0206 in Patients with Periprosthetic Joint Infection (PJI)
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png
0
0
David Anderson
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png
David Anderson2023-05-23 15:56:282023-05-23 16:03:15Peptilogics Reports Positive 90-Day Top Line Interim Data From Phase 1b Trial of PLG0206 in Patients with Periprosthetic Joint Infection (PJI)
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png
0
0
David Anderson
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png
David Anderson2023-04-06 05:00:192023-04-06 05:00:25Peptilogics Completes Phase 1b Trial Enrollment and Will Present Interim Top-line Safety and Tolerability Data of PLG0206 in Patients Undergoing DAIR for the Treatment of Periprosthetic Joint Infection After a Total Knee Arthroplasty at ECCMID 2023
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png
0
0
eallison
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png
eallison2023-02-23 16:34:512023-02-23 16:43:50Peptilogics Hosting Panel Discussion with Leading Industry Experts on the High Unmet Medical Need and Opportunity in Periprosthetic Joint Infections (PJI)
Scroll to top
